Gastrointestinal Adverse Events with Insulin Glargine/Lixisenatide vs. GLP-1RAs
Posted onThis poster will be available at IDF conference on December 2-6, 2019
Author: Doctor Evidence
Efficacy and Safety of Hylan G-F 20 Versus Intra-Articular Corticosteroids
Posted onAUTHORS: Chevalier X., Sheehan B., Whittington C., Ho C., Ngai W., Campos G. CONFERENCE: 2019 ACR/ARP Annual Meeting DATE: November 8-13, 2019. Objective: To evaluate the clinical efficacy and safety of Hylan G-F 20 in comparison with intra-articular corticosteroids in patients with knee OA, using both direct (pairwise) meta-analysis (MA) and network meta-analysis (NMA). See poster
Doctor Evidence is Training AI-Based Technology to Distinguish Real-World Evidence in Literature Search and Monitoring
Posted onSANTA MONICA, Calif., June 3, 2019 /PRNewswire/ — Doctor Evidence (DRE), a global health technology and healthcare research consulting company, continues to breakthrough artificial intelligence (AI) hurdles with the ability to auto-identify research studies that are based on real-world evidence (RWE). Yesterday, at the AcademyHealth Annual Research Meeting in Washington DC, DRE presented a poster entitled, […]
Abatacept in Early Rheumatoid Arthritis A Systematic Literature Review and Network Meta-Analysis
Posted onPoster will be presented at: European Congress of Rheumatology (EULAR) Annual Meeting Category: Rheumatoid arthritis – biological DMARDs June 12-15th, 2019 | Madrid, Spain
Evidence-Based Guidelines: Keeping Current with the Science Between Editions
Posted onAUTHORS: Sandra Zelman Lewis, PhD, David Feller-Kopman, MD, Craig Whittington, PhD, Melanie Golob, MS, Todd Feinman, MD, and Alex Balekian, MD CONFERENCE: ATS International Conference DATE: May 17-22, 2019 Objective: Objective: To test whether AI search technology could be a useful supplementary search engine to rapidly identify new evidence that matches the inclusion criteria of […]
Treatment Landscape in Triple Negative Breast Cancer: A Systematic Literature Review
Posted onAUTHORS: Alex Z. Fu, Yuting Kuang, Mir Sohail Fazeli, Neela Kumar, Catherine Davis CONFERENCE: ESMO Breast Cancer2019 DATE: May 2-4th, 2019 Objective: To describe the evidence landscape on the approved and in-development treatment options for TNBC See poster See references 2019-ESMO-DRE-BMS-Poster
OSTEOARTHRITIS, MOBILITY-RELATED COMORBIDITIES AND MORTALITY: AN OVERVIEW OF SYSTEMATIC REVIEWS
Posted onAUTHORS: Craig Whittington, Ph.D.; Gustavo Campos, M.D.; Raman Mundi, M.D.; Brendan Sheehan, M.D.; Marie-Josée Toutounji, B.Pharm; Yi Xu, MPH.; Wilson Ngai, M.Sc. CONFERENCE: OARSI 2019 DATE: May 2-5, 2019 Objectives Our objective is to examine the relationship between OA and 1) mobility-related comorbidities, specifically diabetes and cardiovascular disease; 2) mortality. See poster 2019-OARSI-DRE-Sanofi-Poster
HIGH MOLECULAR WEIGHT INTRAARTICULAR HYALURONIC ACID FOR THE TREATMENT OF KNEE OSTEOARTHRITIS: NETWORK META-ANALYSIS
Posted onAUTHORS: Charles D. Hummer, M.D., Felix Angst M.D., Emil Schemitsch, M.D., Craig Whittington, PhD, Colleen Manitt, PhD, Wilson Ngai CONFERENCE: OARSI 2019 DATE: May 2-5, 2019 See poster 2019-OARSI-DRE-Sanofi-HMW-Poster Purpose: In 2013, the American Academy of Orthopaedic Surgeons (AAOS) clinical practice guideline (CPG) on the treatment of knee osteoarthritis (OA) made a strong recommendation not […]
Humanistic and Economic Burdens of Triple-Negative Breast Cancer: A Literature Review
Posted onAUTHORS: Alex Z Fu, Boris Breznen, Mir Sohail Fazeli, Marg Hux, Neela Kumar, Catherine Davis CONFERENCE: ISPOR 2019 DATE: May, 18-22, 2019 Objective: To summarize available data related to the humanistic and economic burden of triple-negative breast cancer (TNBC). See poster References 2019-ISPOR-DRE-BMS-Poster-img
Clinical Practice Guidelines: Machine Learning and Natural Language Processing for Automating the Rapid Identification and Annotation of New Evidence
Posted onAUTHORS: Craig Whittington, PhD.; Todd Feinman, M.D.; Sandra Zelman Lewis, PhD., Greg Lieberman, B.S.; Michael del Aguila, PhD. CONFERENCE: Clinical Onmuno-Oncology Smposium (ASCO-SITC) DATE: February 28- March 2, 2019. Background and Objectives In 2018, ASCO published a guideline on how clinicians should manage immunerelated adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors (ICPis). 2019-ASCO-SITC-DRE-Poster-img See poster